Adverse events and humoral response after two doses of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) mRNA vaccine in the hospital personnel of a cardiopulmonary tertiary-care center

Infect Control Hosp Epidemiol. 2022 Oct;43(10):1532-1534. doi: 10.1017/ice.2021.321. Epub 2021 Jul 15.

Authors

Erica De Vita^#^{1

2}, Francesco Sbrana^#¹, Filippo Quattrone^{2

3}, Beatrice Dal Pino¹, Monica Megaro¹, Roberta Lombardi¹, Concetta Prontera¹, Claudio Passino^{1

3}, Maurizio Petrillo¹

Affiliations

¹ Fondazione Toscana "Gabriele Monasterio,"Pisa, Italy.
² Management and Healthcare Laboratory, Institute of Management and Department, EMbeDS, Scuola Superiore Sant'Anna, Pisa, Italy.
³ Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.

^# Contributed equally.

No abstract available

MeSH terms

Antibodies, Viral
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Personnel, Hospital
SARS-CoV-2*
Vaccines, Synthetic
mRNA Vaccines

Substances

Antibodies, Viral
Vaccines, Synthetic
COVID-19 Vaccines